Knights of Columbus Asset Advisors LLC Has $5.40 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Knights of Columbus Asset Advisors LLC grew its stake in Stryker Co. (NYSE:SYK) by 1.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 18,038 shares of the medical technology company’s stock after acquiring an additional 312 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Stryker were worth $5,402,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Freedom Wealth Alliance LLC acquired a new position in shares of Stryker in the 4th quarter valued at $26,000. Farmers & Merchants Trust Co of Chambersburg PA increased its holdings in Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Quarry LP bought a new stake in shares of Stryker in the first quarter valued at about $27,000. HBC Financial Services PLLC acquired a new position in shares of Stryker during the fourth quarter worth about $37,000. Finally, Bourgeon Capital Management LLC bought a new position in shares of Stryker during the fourth quarter worth about $37,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now directly owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The disclosure for this sale can be found here. Insiders sold 212,109 shares of company stock valued at $72,845,768 over the last quarter. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

SYK stock opened at $325.43 on Friday. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The stock has a market cap of $123.82 billion, a price-to-earnings ratio of 39.45, a P/E/G ratio of 2.64 and a beta of 0.89. The company has a 50 day simple moving average of $350.01 and a 200 day simple moving average of $312.50.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. Stryker’s revenue was up 11.8% compared to the same quarter last year. During the same period in the prior year, the company earned $3.00 EPS. Research analysts anticipate that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is currently 38.79%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on SYK shares. Truist Financial upped their price target on Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research report on Wednesday, January 31st. Wells Fargo & Company lifted their target price on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st. Royal Bank of Canada increased their price target on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $340.45.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.